We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Lonza Launches A Innovative Concept in Biological Manufacturing and Development

Lonza Launches A Innovative Concept in Biological Manufacturing and Development content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute


Lonza’s commitment to constant innovation and adding value to its customers and partners is today demonstrated by the launch of Ibex™ Solutions – a unique addition to its current offering.

 

Ibex™ Solutions is an innovative new biological development and manufacturing concept, coupling flexibility in facility-build-out with fully tailored business models and leveraging Lonza's expertise and service network in Visp (CH). Construction began in June with a formal groundbreaking ceremony expected in the second half of 2017. Several hundred new positions are expected to be created.

 

Ibex™ biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies – mammalian, microbial, cellular or bio-conjugate – and from late discovery to manufacture. This flexibility gives customers complete freedom in facility design and implementation, and the ability to respond rapidly as their needs evolve.

 

Responsiveness is further enhanced by the integration of the Ibex™ biomanufacturing complex into the Visp site with its experienced workforce and established service networks.

 

Ibex™ Solutions include highly flexible models to match and adapt to each customer’s expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by 12 months or more. These advantages contribute to a significant de-risking of major strategic investment decisions.

 

Lonza’s Pharma&Biotech COO, Marc Funk, commented: “Lonza has been creating innovative manufacturing and production solutions for 120 years, and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world. We have been working with our partners to understand what we can offer that will really change the game for them, and that’s why we have created Ibex™.”

 

 

Ibex™ Solutions – Features


·         Modular biomanufacturing complex

·         A partner with expertise in multiple technologies and

          proven track record

·         Technology-independent construction

·         Flexible engagement options

·         Existing infrastructure and support networks

·         Facilities embedded in the ecosystem of Visp (CH)


 

Ibex™ Solutions – Benefits


·         Faster time-to-market

·         Full build-out flexibility

·         Significant reduction in investment risk

·         Tailored business and ownership models, providing

           higher transparency and flexibility

·         Cost-effective build-out and fast ramp-up

·         Assured delivery, simplified with supply chain

·         Stable workforce, IP protection and favorable taxation

          environment